| 000 | 01859 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515185359.0 | ||
| 264 | 0 | _c20100329 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.1080/10428190903186494 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEve, Heather E | |
| 245 | 0 | 0 |
_aThe Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cOct 2009 |
||
| 300 |
_a1709-11 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Comparative Study; Letter; Randomized Controlled Trial; Validation Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurvival |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aGambell, Jo | |
| 700 | 1 | _aSmith, Paul | |
| 700 | 1 | _aQian, Wendi | |
| 700 | 1 | _aRule, Simon A J | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 50 _gno. 10 _gp. 1709-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/10428190903186494 _zAvailable from publisher's website |
| 999 |
_c19155005 _d19155005 |
||